Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Remdesivir has been established as a safe treatment for patients with COVID-19. However, given the SARS-CoV-2 random mutations, 3CL protease inhibitors have been studied in recent randomized controlled trials. Therefore, this meta-analysis aims to compare 3CL protease inhibitors...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicole Jean Lee, Eric Shih Katsuyama, Christian Ken Fukunaga, Wilson Falco Neto, Ana Carolina Covre Coan, Hilaria Saugo Faria, Eduardo Alexandrino Medeiros
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Virology Journal
Subjects:
Online Access:https://doi.org/10.1186/s12985-025-02899-0
Tags: Add Tag
No Tags, Be the first to tag this record!